Numéros thématiques

• 2021

  • Practical management of patients on hydroxychloroquine
    This supplement was produced in partnership with FAI2R, SFR, SNFMI, SFD, and SOFREMIP, under the aegis of CRI

    Volume 88 - Numéro 5 Supplément 1, (décembre 2021)

  • Practical management of patients on anti-IL6R therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
    This supplement was published with support from the Club Rhumatismes et Inflammation (CRI)

    Volume 88 - Numéro 4 Supplément 1, (juin 2021)

  • Practical management of patients on anti-IL17 therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
    This supplement was published with institutional funding provided by Lilly and Novartis

    Volume 88 - Numéro 3 Supplément 1, (mai 2021)

  • Practical management of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI)
    This supplement was published with institutional funding provided by AbbVie, Amgen, Biogen, Celltrion, Fresenius Kabi, MSD, Mylan, Pfizer, Sandoz and UCB

    Volume 88 - Numéro 2 Supplément 1, (mai 2021)

• 2019

  • Practical management of patients on Janus kinase inhibitor (JAKi) therapy

    Volume 86 - Supplément 1, pp.eS1-eS103 (octobre 2019)

• 2015

  • Defining a Role for Canakinumab and IL-1 inhibition in Difficult-to-Treat Gouty Arthritis

    Volume 82 - Supplément 1, pp.eS1-eS32 (octobre 2015)

• 2014

  • Biologic targeted therapies in pediatric rheumatology: Fact sheets developed by the Club Rhumatismes et Inflammations (CRI), an organization endorsed by the French Society for Rheumatology (SFR)

    Volume 81 - Supplément 1, pp.2-48 (février 2014)

  • Biologic targeted therapies in pediatric rheumatology: Fact sheets developed by the Club Rhumatismes et Inflammations (CRI), an organization endorsed by the French Society for Rheumatology (SFR)

    Volume 80 - Numéro eS1, pp.5-48 (février 2014)

• 2012

  • Management of Stress Fractures and Imaging of Possibly Malignant Vertebral Fractures Update on Bone in Kidney Disease: 3rd National ODISSEE Meetings (Osteoporosis: DIagnosis and Surveillance of SEvErity)

    Volume 79 - Supplément 2, pp.S85-S113 (octobre 2012)

  • Abatacept therapy and safety management

    Volume 79 - Supplément 1, pp.3-84 (mars 2012)

• 2011

  • Male osteoporosis and glucocorticoid-induced osteoporosis 2nd National ODISSEE Meetings (Osteoporosis: DIagnosis and Surveillance of SEvErity)

    Volume 78 - Supplément 2, pp.S189-S226 (décembre 2011)

  • TNF alpha antagonist therapy and safety monitoring

    Volume 78 - Supplément 1, pp.15-185 (mai 2011)

• 2010

  • First National ODISSEE Meetings (Osteoporosis: DIagnosis and Surveillance of SEvErity) Managing Severe Osteoporosis : from Diagnosis to Treatment

    Volume 77 - Supplément 2, pp.S101-S141 (décembre 2010)

  • Tocilizumab: Therapy and safety management

    Volume 77 - Supplément 1, pp.S3-S100 (juin 2010)

• 2009

  • Abatacept therapy and safety management

    Volume 76 - Supplément 1, pp.S3-S55 (mai 2009)